Morgan Stanley Maintains Overweight on SI-BONE, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Drew Ranieri has maintained an Overweight rating on SI-BONE (NASDAQ:SIBN) and increased the price target from $25 to $26.
February 27, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reaffirmed its Overweight rating on SI-BONE and raised the price target from $25 to $26.
The upgrade in the price target by a reputable analyst like Drew Ranieri from Morgan Stanley is a strong positive signal for SI-BONE. It suggests confidence in the company's future performance and growth prospects, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100